在与GBA相关的新发帕金森病患者中,胆固醇内尔化拓
Sofie Slingerland1, Sygrid van der Zee1,2, Giulia Carli3
1Department of Neurology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Brain : a journal of neurology
|September 25, 2023
概括
GBA1中的遗传突变与帕金森病 (PD) 有关. 在临床差异出现之前,GBA1-PD患者表现出更严重的胆固醇系统缺陷,可以通过18F-FEOBV PET成像检测到,甚至在临床差异出现之前.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 医疗成像医学成像
背景情况:
- GBA1突变是帕金森病 (PD) 的常见遗传风险因素.
- GBA1-PD患者经常出现早期发病,进展更快,以及更严重的认知和运动症状.
- 这些临床特征表明在GBA1-PD中存在底层胆固醇系统功能障碍.
研究的目的:
- 通过使用18F-FEOBV PET来研究新诊断的,未经治疗的帕金森病患者的胆固醇系统变化,这些患者有或没有GBA1突变.
- 探索GBA-PD中胆性缺陷和临床特征之间的关系.
- 为了确定GBA-PD和非GBA-PD之间是否存在不同的胆固醇内置模式.
主要方法:
- 123名从未接受过治疗的PD患者接受了全基因GBA1测序,神经心理评估,运动评估 (UPDRS),MRI和18F-FEOBV PET成像.
- 用voxel-wise和volume of interest (VOI) 分析来比较GBA-PD携带者与非GBA1突变携带者 (非GBA-PD) 之间的区域胆固醇内置.
- 子相似系数量化了成像地图之间的重叠.
主要成果:
- 在诊断时,在GBA-PD和非GBA-PD之间没有观察到显著的临床或多巴胺作用差异.
- 与对照组相比,这两组都显示了18F-FEOBV结合的减少,这表明胆固醇缺乏.
- 与非GBA-PD患者相比,GBA-PD患者在皮质区域 (头,头,头,额头) 特别是左侧近海马回形中表现出更广泛的胆性化,与非GBA-PD患者相比.
结论:
- 在新的GBA-PD和非GBA-PD中,胆固醇系统的变化呈现出不同的模式.
- 这些胆固醇差异可以通过18F-FEOBV PET检测到,即使临床表型还不能区分.
- 建议对更大的队列进行进一步验证,以确认这些发现及其临床影响.
相关概念视频
01:15Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
01:24Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:15Cholinergic Receptors: Nicotinic
2.9K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.9K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
709
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
709
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K